Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12.
No abstract available

Keywords: bortezomib; chemotherapy; plasmablastic lymphoma; survival.

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bortezomib / administration & dosage*
  • Bortezomib / adverse effects
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Plasmablastic Lymphoma / drug therapy*
  • Plasmablastic Lymphoma / mortality*
  • Plasmablastic Lymphoma / pathology
  • Prednisone / administration & dosage
  • Prednisone / adverse effects
  • Retrospective Studies
  • Survival Rate
  • Vincristine / administration & dosage
  • Vincristine / adverse effects

Substances

  • Vincristine
  • Bortezomib
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • EPOCH protocol